Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Rare Diseases

Lung Neoplasms

Small Cell Lung Carcinoma

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Small Cell Lung Cancer

Antineoplastic Agents

All Drugs and Chemicals

Etoposide

Cisplatin

Etoposide phosphate

Enzyme Inhibitors

Patients in this group will receive concurrent twice-daily radiotherapy by SIB technique (95%PGTV 54Gy, 95%PTV 45Gy,both in 30 twice-daily fractions over 3 weeks, 5 days per week) and chemotherapy (etoposide and cisplatin).

Patients in this group will receive concurrent twice-daily standard radiotherapy (95%PTV 45Gy in 30 twice-daily fractions over 3 weeks, 5 days per week, without SIB) and chemotherapy (etoposide and cisplatin).

patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy

patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy

Standard

Anhui Shi, Doctor

This trial is a multicenter, perspective, non-blinded, randomized controlled phase 3 trial. In order to establish whether the SIB technique can improve the results of twice-daily chemo-RT for patients with LS-SCLC, the investigators will primarily compare survival of patients treated with standard chemotherapy (cisplatin and etoposide) and either SIB twice-daily RT or standard dose twice-daily RT.

Three hundred and twenty-six patients with a histological or cytological proven diagnosis of SCLC will be recruited from 35 centers in 14 areas including provinces, municipalities and autonomous region, from May 2017 to May 2020.

Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC

Twice-daily Radiotherapy by Simultaneous Integrated Boosting Technique Versus Twice-daily Standard Radiotherapy for Patients With Limited-stage Small Cell Lung Cancer: a Multicenter, Randomized, Controlled, Phase III Study

from the starting date of treatment until the date of death from any cause

from the starting date of treatment until the date of local disease progression

from the staring date of treatment until the date of distant metastasis

assessed from completed questionnaires. Assessments using Physicians Global Assessment to measure quality of life.

acute toxicity (defined as toxicity occurring between the start of treatment and up to 3 months after completion of treatment, and assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[version 5.0\]), late toxicity (more than 3 months after completion of treatment, and assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[version 5.0\])

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC	NCT03214003	Small Cell Lung... Radiotherapy	SIB Standard	18 Years - 70 Years	Peking University Cancer Hospital & Institute
Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC	NCT03214003	Small Cell Lung... Radiotherapy	SIB Standard	18 Years - 70 Years	Peking University Cancer Hospital & Institute

Spots Global Cancer Trial Database for simultaneous integrated boosting technique